Support MPCC

1 out of 36 men will die of prostate cancer. Get involved.

Our Mission

Our Mission

The Massachusetts Prostate Cancer Coalition (MPCC) educates, connects, and supports men-at-risk, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.

Our Vision: Educate | Inform | Advocate

 

State of the Art — State of the Disease

Friday, May 12, 2017, Boston Marriott Copley Place, Boston, MA
Go here to see photos and presentations from the Symposium.

Five Facts about Prostate Cancer

Five Facts about Prostate Cancer
  1. 1
    Prevalence
    Prostate cancer is the most common (non-skin) cancer in American men, representing 33% of all new cases.
  2. 2
    Prostate cancer affects 1 in 7 men.
    1 in 7 men will be diagnosed with prostate cancer during their lifetime. In 2015, nearly 6,000 men were diagnosed with prostate cancer in Massachusetts, with an incidence rate of 4%-6% higher than the national average.
  3. 3
    Second leading cause of cancer death in men.
    Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. 
  4. 4
    Prostate cancer top risk factors.

    Ethnicity

    African-American men are twice as likely to die of prostate cancer as white men. Asian-Americans and Hispanic/Latinos have lower rates of prostate cancer than non-Hispanic white men.

    Age

    Prostate cancer occurs mainly in older men. About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 66.

  5. 5
    This year over 27,000 men will die of prostate cancer.

    Yet, most men diagnosed with prostate cancer will not die from it. In fact, more than 2.5 million men in the United States who have been diagnosed with prostate cancer are still alive today.


Statistics from The American Cancer Society 2017

We need your support! Become a Member or Donate to MPCC today.

Save the Date: 21st Annual Prostate Cancer Symposium — May 4, 2018, Newton Marriott, Newton, MA

UK-based scientists have developed a new three-in-one blood test able to identify the patients with advanced prostate cancer most likely to benefit from PARP inhibitors, with the potential to ‘transform’ treatment of the disease. Read more read more →

Researchers at Moffitt Cancer Center have revealed the mechanism that explains the transformation process of prostate cells into castration-resistant cancer cells. They’ve also identified a new drug candidate that targets this specific mechanism, preventing the growth and proliferation of these aggressive and deadly cancer cells. Read more read more →